注释ID

981851641

变量_单倍型

NAT2*4, NAT2*5D, NAT2*6B, NAT2*7A, NAT2*14A, NAT2*19

基因

NAT2

药物名称(英)

isoniazid

药物名称(中)

异烟肼

PMID

23150149

类型

Dosage,"Metabolism/PK"

含义

yes

记事

Patients were given an isoniazid dose based on NAT2 acetylator status or a standard dose. Slow acetylators (carriers of two variant alleles *19, *14, *5, *6, or *7) who had their dose adjusted had a reduced incidence of liver injury as compared to those who received a standard dose, and fast acetylators (*4/*4, either given standard dose or 1.5x standard dose) who had their dose adjusted had a reduced incidence of early treatment failure (at 8 weeks) as compared to those who received a standard dose.

专家论述

NAT2 *4/*4 (assigned as rapid acetylator phenotype) is associated with increased dose of isoniazid in people with Tuberculosis as compared to NAT2 *19 + *14A + *5D + *6B + *7A (assigned as slow acetylator phenotype) .

等位基因

*4/*4

专家评论

备注

变体注释摘要

id	研究类型	特征类型
17868	clinical trial	Study Cohort
17867	clinical trial	Study Cohort